Selling and Marketing Expense of Axsome Therapeutics, Inc. from 31 Dec 2022 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
Summary
Axsome Therapeutics, Inc. quarterly and annual Selling and Marketing Expense in USD history and change rate from 31 Dec 2022 to 31 Dec 2025.
  • Axsome Therapeutics, Inc. Selling and Marketing Expense for the quarter ending 31 Dec 2025 was $134,538,000, a 69% increase year-over-year.
  • Axsome Therapeutics, Inc. Selling and Marketing Expense for the twelve months ending 31 Dec 2025 was $440,402,000, a 50% increase year-over-year.
  • Axsome Therapeutics, Inc. annual Selling and Marketing Expense for 2025 was $440,402,000, a 50% increase from 2024.
  • Axsome Therapeutics, Inc. annual Selling and Marketing Expense for 2024 was $293,355,000, a 24% increase from 2023.
  • Axsome Therapeutics, Inc. annual Selling and Marketing Expense for 2023 was $237,228,000, a 127% increase from 2022.
Source SEC data
View on sec.gov
Selling and Marketing Expense, Trailing 12 Months (USD)
Selling and Marketing Expense, Quarterly (USD)
Selling and Marketing Expense, YoY Quarterly Change (%)
Selling and Marketing Expense, Annual (USD)
Selling and Marketing Expense, YoY Annual Change (%)

Axsome Therapeutics, Inc. Quarterly Selling and Marketing Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $440,402,000 $134,538,000 +$55,121,000 +69% 01 Oct 2025 31 Dec 2025 10-K 23 Feb 2026 2025 FY
Q3 2025 $385,281,000 $114,200,000 +$46,014,000 +67% 01 Jul 2025 30 Sep 2025 10-Q 03 Nov 2025 2025 Q3
Q2 2025 $339,267,000 $99,376,000 +$24,820,000 +33% 01 Apr 2025 30 Jun 2025 10-Q 04 Aug 2025 2025 Q2
Q1 2025 $314,447,000 $92,288,000 +$21,092,000 +30% 01 Jan 2025 31 Mar 2025 10-Q 05 May 2025 2025 Q1
Q4 2024 $293,355,000 $79,417,000 01 Oct 2024 31 Dec 2024 10-K 23 Feb 2026 2025 FY
Q3 2024 $68,186,000 01 Jul 2024 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 $74,556,000 01 Apr 2024 30 Jun 2024 10-Q 04 Aug 2025 2025 Q2
Q1 2024 $71,196,000 01 Jan 2024 31 Mar 2024 10-Q 05 May 2025 2025 Q1

Axsome Therapeutics, Inc. Annual Selling and Marketing Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $440,402,000 +$147,047,000 +50% 01 Jan 2025 31 Dec 2025 10-K 23 Feb 2026 2025 FY
2024 $293,355,000 +$56,127,000 +24% 01 Jan 2024 31 Dec 2024 10-K 23 Feb 2026 2025 FY
2023 $237,228,000 +$132,569,000 +127% 01 Jan 2023 31 Dec 2023 10-K 23 Feb 2026 2025 FY
2022 $104,659,000 01 Jan 2022 31 Dec 2022 10-K 18 Feb 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.